To exemplify this association between enhanced YAP/TAZ activity and cancer prognosis, a significant decrease in survival time is observed in patients across a variety of The Cancer Genome Atlas (TCGA) cohorts that exhibit an above median average expression of bona fide downstream targets of YAP/TAZ [12]. The gene discussed is WWTR1; the disease is cancer.